Protein kinase inhibitor
Volasertib (also known as BI 6727) is a small molecule drug being studied for its ability to inhibit a protein called PLK1. It is currently being researched in clinical trials for several types of cancer, including acute myeloid leukemia and non-small cell lung carcinoma.
How it worksVolasertib works by blocking a specific protein called serine/threonine-protein kinase PLK1, which is involved in cell division.
How to take
This drug is currently in clinical testing phases and is not yet widely approved for general use in all listed conditions. It has reached Phase 3 clinical trials for acute myeloid leukemia.
Talk to your doctor
Questions to ask
- ·Is Volasertib appropriate for my type of cancer?
- ·What are the potential risks of Volasertib?
- ·How is Volasertib administered in clinical trials?
Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.
